News

Trikafta Costs to be Subsidized for Eligible Australians

Beginning April 1 the Australian government will subsidize the cost of Trikafta (elexacaftor/tezacaftor/ivacaftor) for patients with cystic fibrosis (CF) under the Australian Pharmaceutical Benefits Scheme (PBS), dramatically reducing out-of-pocket expenses for eligible Australians. The subsidy was made possible by a reimbursement agreement reached between Trikafta’s developer, Vertex…

Increased Education Crucial to Improving Rare Disease Care, Survey Finds

Healthcare providers involved in diagnosing and treating rare diseases believe that increased physician education and collaboration with specialized facilities will have the greatest positive impact on treating these conditions over the next five years, according to results from a 2021 survey. Definitive Healthcare, a healthcare commercial intelligence company, conducted…

Bacteria Boosts Anti-fungal Medicine’s Killing Power in CF Study

Co-infection with the bacterium Pseudomonas aeruginosa can increase the potency of therapies that kill Candida albicans, an infectious fungus, according to a new study. The study, “Pseudomonas Synergizes with Fluconazole against Candida during Treatment of Polymicrobial Infection,” was published in Infection and Immunity. Pseduomonas and Candida are both microorganisms…

CFF ResearchCON on Tap Online in April With Latest CF Updates

Registration is open for this year’s ResearchCON, a free two-day online educational event that seeks to present the latest in cystic fibrosis (CF) research, science, and care in a way that’s accessible, engaging, and easy to understand. The Cystic Fibrosis Foundation (CFF) event will be held on…